hypericum and Obesity

Diets included high-fat (HFD) and high calories intake is correlated with greater risk of obesity and oxidative stress, which lead to increase the risk of related diseases such as cardiovascular and metabolic disease. In the present study, we have examined the hypolipidemic activity of Hypericum Scabrum extract on HFD fed rats. Fifty-four male Wistar rats divided into six groups: 1) control, 2) H. Scabrum extract (100 mg/kg gavage per day), 3) H. Scabrum extract (300 mg/kg), 4) HFD, 5) HFD and H. Scabrum extract (100 mg/kg), 6) HFD and H. Scabrum extract (300 mg/kg). The groups were fed their diet and treatment for 3 months. Biochemical analysis showed elevated lipid serum profile in HFD rats compared to control group. H. Scabrum extract supplementation significantly ameliorated triglyceride, total cholesterol and LDL-cholesterol. H. Scabrum extract supplementation leading to increase HDL-cholesterol in HFD treated groups. This experiment showed that H. Scabrum extract decreased HFD complications and might be beneficial herbal drug for treatment of hyperlipidemia and obesity.

Topics: Animals; Diet, High-Fat; Hypericum; Liver; Male; Obesity; Plant Extracts; Rats; Rats, Wistar; Triglycerides

Stimulation of adipose tissue thermogenesis is regarded as a promising avenue in the treatment of obesity. However, pharmacologic engagement of this process has proven difficult. Using the Connectivity Map (CMap) approach, we identified the phytochemical hyperforin (HPF) as an anti-obesity agent. We found that HPF efficiently promoted thermogenesis by stimulating AMPK and PGC-1α via a Ucp1-dependent pathway. Using LiP-SMap (limited proteolysis-mass spectrometry) combined with a microscale thermophoresis assay and molecular docking analysis, we confirmed dihydrolipoamide S-acetyltransferase (Dlat) as a direct molecular target of HPF. Ablation of Dlat significantly attenuated HPF-mediated adipose tissue browning both in vitro and in vivo. Furthermore, genome-wide association study analysis indicated that a variation in DLAT is significantly associated with obesity in humans. These findings suggest that HPF is a promising lead compound in the pursuit of a pharmacological approach to promote energy expenditure in the treatment of obesity.

Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Binding Sites; Cold Temperature; Dihydrolipoyllysine-Residue Acetyltransferase; Humans; Hypericum; Mice; Mice, Inbred C57BL; Mice, Obese; Mitochondrial Proteins; Molecular Docking Simulation; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phloroglucinol; Signal Transduction; Terpenes; Thermogenesis; Uncoupling Protein 1; Up-Regulation

Obesity is a low-grade inflammatory disease that is getting increasingly common among adults and children and causes different complications. Insulin resistance, Type II diabetes, atherosclerosis, metabolic syndrome and hypertension are among the major health problems, that are associated with obesity. Some medications are used to treat obese individuals and metabolic surgery is recommended, if appropriate, for individuals with a BMI ≥ 40. Due to the fact that medications and metabolic surgery are not tolerated by all, researchers focus on alternative therapies. Medicinal plants comprise the most important group of these alternative treatments. Hypericum perforatum L. is the medicinal plant, which we focused on in this study. Hypericum perforatum L. has been recognized as a medicinally valuable plant for over 2000 years. It has been used for generations to treat anxiety, depression, insomnia, gastritis, hemorrhoids, wounds, and burns. Recent studies have indeed shown promising effects for the treatment of obesity. In this study, 3T3-L1 adipocytes were used to mimic the adipocyte differentiation associated with obesity in cellular terms. Lipoprotein lipase (Lpl), Diacylglycerol-O-acyltransferase 1 (Dgat1), Fatty acid synthase (Fasn) markers were used to study the lipid accumulation, and Collagen V (ColV) was used to study cell elasticity to investigate the relationship of the effects of the administration of Hypericum perforatum L. with obesity.

Topics: 3T3-L1 Cells; Animals; Cell Differentiation; Collagen Type V; Hypericum; Lipid Metabolism; Mice; Obesity; Plant Extracts; Plants, Medicinal

Natural product Hypericum perforatum L. has been used in folk medicine to improve mental performance. However, the effect of H. perforatum L. on metabolism is still unknown. In order to test whether H. perforatum L. extract (EHP) has an effect on metabolic syndrome, we treated diet induced obese (DIO) C57BL/6J mice with the extract. The chemical characters of EHP were investigated with thin-layer chromatography, ultraviolet, high-performance liquid chromatography (HPLC), and HPLC-mass spectrometry fingerprint analysis. Oral glucose tolerance test (OGTT), insulin tolerance test (ITT), and the glucose infusion rate (GIR) in hyperinsulinemic-euglycemic clamp test were performed to evaluate the glucose metabolism and insulin sensitivity. Skeletal muscle was examined for lipid metabolism. The results suggest that EHP can significantly improve the glucose and lipid metabolism in DIO mice. In vitro, EHP inhibited the catalytic activity of recombinant human protein tyrosine phosphatase 1B (PTP1B) and reduced the protein and mRNA levels of PTP1B in the skeletal muscle. Moreover, expressions of genes related to fatty acid uptake and oxidation were changed by EHP in the skeletal muscle. These results suggest that EHP may improve insulin resistance and lipid metabolism in DIO mice.

Topics: Animals; Diet, High-Fat; Fatty Acids; Glucose; Glucose Tolerance Test; Humans; Hypericum; Insulin Resistance; Lipid Metabolism; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Obesity; Plant Components, Aerial; Plant Extracts; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Recombinant Proteins

This study was carried out to assess the anti-obesity effect of Hypericum silenoides Juss. and Hypericum philonotis Cham. & Schlecht. in male Wistar rats fed with a cafeteria diet.. Adult male Wistar rats with an initial body weight of 290-320 g were used in this trial. The rats were fed with a cafeteria diet for 77 days. Hypericum species were administered orally at a dose of 10, 30 or 100 mg/kg of body weight daily for 35 days. Body weight, food intake, anorexic effect and various biochemical parameters, such as serum glucose, lipid profile, alanine transaminase (ALT), aspartate transaminase (AST) and atherogenic index (AI), were assessed. Additionally, inhibitory lipase activity assay and forced swimming test were also carried out.. Oral administration of H. silenoides and H. philonotis extracts resulted in a significant decrease in body weight and serum glucose levels in obese male Wistar rats. Treatment with aqueous extract of H. silenoides showed anorexic and antidepressant effects and also significantly (P < 0.05) decreased total cholesterol, triglycerides and high-density lipoprotein-cholesterol, while low-density lipoprotein-cholesterol, AI, AST and ALT were not changed. The dichloromethane extract of H. silenoides (half maximal inhibitory concentration (IC₅₀ ) = 262.79 ± 0.09 μg/ml) and hexane extract of H. philonotis (IC₅₀  = 162.60 ± 0.02 μg/ml) showed the most potent lipase inhibitory activity.. Some H. silenoides and H. philonotis extracts showed a significant anti-obesity activity in cafeteria-diet-fed rats. This research provides the first scientific support for the use of the Hypericum genus for weight reduction in Mexican folk medicine.

Topics: Animals; Anti-Obesity Agents; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethnopharmacology; Hyperglycemia; Hypericum; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipase; Male; Medicine, Traditional; Mexico; Obesity; Plant Components, Aerial; Plant Extracts; Random Allocation; Rats; Rats, Wistar

Topics: Cognition Disorders; Consumer Product Safety; Depression; Dietary Supplements; Ephedrine; Ginkgo biloba; Humans; Hypericum; Obesity; Panax; Phytotherapy; Plants, Medicinal; United States; United States Food and Drug Administration